Theriva Biologics (TOVX) Net earnings per share growth forecast for next year

Symbol and logo of brand Synthetic Biologics (TOVX)

Theriva Biologics, Inc. (TOVX) is monetizing the development of VCN-01 to combat pancreatic and ocular cancers, relying exclusively on research alliances with oncology centers. The modeled EPS growth for the next fiscal year serves as an indicator of market expectations, where the 19.60 level reflects the current magnitude of the profit forecast. Company management is aggressively developing its innovative immunotherapy platform through a series of clinical trials.

TOVX - Synthetic Biologics Earnings growth forecast for next year over the range 04/28/2023 - 11/18/2026

Metric breakdowns and analytics for Synthetic Biologics (TOVX)

- price and consensus price forecast:
Analysis of all company metrics:Synthetic Biologics
Core merchandise of Theriva Biologics Inc

This indicator reflects the dynamics of analysts' consensus forecasts for earnings per share changes, eliminating reporting time lags through daily updates of expectations. By analyzing the projected EPS growth rate for the coming year, an investor assesses the probability of commercial success for the oncolytic platforms of Theriva Biologics, Inc. (TOVX), where any sharp fluctuations in the line signal critical changes in clinical trial results.

Direct competitors

Net earnings per share growth forecast for next year immunitybio.com|Expected earnings per share growth for next year immunocore.com (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics Inc (JANX)|Expected earnings per share growth for next year Arcus Bio RCUS|Zymeworks Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Corp TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (immatics.com) - Projected earnings per share growth rate for next year|Xencor Inc. (XNCR) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Compass Bio (CMPX)|Expected earnings per share growth for next year REPL|LYEL - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year IPHA (Innate Pharma, S.A.)|Projected earnings per share increase next year PYXS|Earnings growth forecast for next year CGEN (Compugen Ltd.)|Expected earnings per share trend next year IOBT|sutrobio.com - Earnings growth forecast for next year|Expected net earnings per share growth next year MiNK Therapeutics, Inc|Werewolf (HOWL) - Net earnings per share growth forecast for next year|Immix Biopharma Inc. - Expected earnings per share trend next year|ALXO (alxoncology.com) - Earnings growth forecast for next year|Cue Biopharma, Inc. - Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year pdsbiotech.com (PDSB)|SONN: Net earnings per share change forecast for next year|MAIA Biotech - Expected earnings per share growth for next year|liminatuspharma.com (LIMN) - Expected net earnings per share growth next year|LVTX - Net earnings per share growth forecast for next year|NXTC (NextCure) - Projected earnings per share growth rate for next year|LPTX: Earnings growth forecast for next year|Projected earnings per share growth rate for next year INTS|Net earnings per share growth forecast for next year Sensei Biotherapeutics, Inc.|Gritstone bio (GRTS) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year KA|Consensus forecast of earnings per share growth for next year NexImmune Inc|Net earnings per share growth forecast for next year turnstonebio.com TSBX|Consensus forecast of earnings per share growth for next year Vaccinex Inc (VCNX)|HARP - Net earnings per share growth forecast for next year